Nanotechnology, while still largely in preclinical stages for drug delivery, is thought to be on the cutting edge of the field as a means to develop highly specific, targeted and unobstrusive treatments. And as the research field inches closer to commercialization, the manufacture of such particles will present a bottleneck for companies looking to make a dent if upscaling processes aren't already in place.
Researchers create a system that can scale-up production of the smallest -- but among the most useful -- materials of this century Nanoparticles - tiny particles 100,000 times smaller than the width...
Two startups--one from the U.K. and another from the Netherlands--have teamed up to combine a robotic device with a gene therapy for high-precision delivery to the subretinal space. It will begin as a development partnership as the companies establish the technique, but the plan is to move into human trials together down the road.
Contract drugmaker and delivery specialist Consort Medical has signed with eyecare company Precision Ocular to build up Precision's drug delivery system using Consort's device and manufacturing capabilities. As part of the deal, Consort joined a $19 million financing round for the U.K. startup.
Vaginal rings that release antiretroviral drugs to prevent AIDS hold promise in developing countries to stem the spread of the disease and empower women by allowing them to control their own drug regimens. And research communities are hailing two new trials in Africa for safety and efficacy.
After tumor removal surgery, any part of the tumor that is left could potentially once again be harmful and spread. Now, using clusters of gold nanoparticles and short bursts of infrared light, researchers have homed in on those remaining cells to eradicate traces of the tumor with precision.
Researchers at the University of Alabama at Birmingham have designed "smart" nanoparticles for cancer drug delivery, and they've found that changes in shape and elasticity could play an important role in their effectiveness as treatment carriers.